0001213900-24-020938.txt : 20240308 0001213900-24-020938.hdr.sgml : 20240308 20240308122504 ACCESSION NUMBER: 0001213900-24-020938 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Haoxi Health Technology Ltd CENTRAL INDEX KEY: 0001954594 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-ADVERTISING AGENCIES [7311] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41933 FILM NUMBER: 24733249 BUSINESS ADDRESS: STREET 1: 801/802, TOWER C, BUILDING 103 STREET 2: HUIZHONGLI, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100101 BUSINESS PHONE: 86-10-13311587976 MAIL ADDRESS: STREET 1: 801/802, TOWER C, BUILDING 103 STREET 2: HUIZHONGLI, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100101 6-K 1 ea0201431-6k_haoxi.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2024

Commission File Number: 001-41933

Haoxi Health Technology Limited

Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District

Beijing, China

+86-10-13311587976

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On March 8, 2024, EF Hutton LLC, as representative of the underwriters of the initial public offering of Haoxi Health Technology Limited’s (the “Company”) exercised its over-allotment option in full to purchase an additional 360,000 Class A ordinary shares of the Company at the public offering price of US$4.00 per share. The closing for the sale of the over-allotment shares took place on March 8, 2024. As a result, the gross proceeds of the Company's initial public offering, including the proceeds from the sale of the over-allotment shares, totaled US$11,040,000, before deducting underwriting discounts and other related expenses.

This report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Haoxi Health Technology Limited

Date: March 8, 2024	By:	/s/ Zhen Fan
	Name:	Zhen Fan
	Title:	Chief Executive Officer